The Effect of Itraconazole on the Clinical Outcomes of Patients with Advanced Non Small Cell Lung Cancer Receiving Platinum Based Chemotherapy

Abstract

ung cancer (LC) remains the most common cancer diagnosed and greatest cause of cancer-related death worldwide as it accounts for 17% and 9% of all cancers in men and women respectively and it represents 19% of all cancer-related deaths It was the most frequently diagnosed cancer in males with an estimated 1.2 million incident cases worldwide Non-small cell lung cancer (NSCLC) accounts for over 85% of all lung cancer and often considered a disease of the older population with a median age at diagnosis of about 70 years. The treatment strategy should be tailored upon multiple factors such as tumor histology, molecular pathology, age, performance state (PS) (0-2), comorbidities and the patient’s preference in a multidisciplinary tumor board open discussion. Chemotherapy with platinum doublets should be considered in all stage IV NSCLC patients without an actionable oncogenic driver, without major comorbidities and PS 0–2. Chemotherapy was associated with an improved survival (one-year survival rate, 29 versus 20 percent; hazard ratio [HR] 0.77, 95% CI 0.71-0.83), this survival benefit was independent